Showing results (271-280 of 396) with videos related to
Sort By:
Pageof 40
Respiratory Medicine|January 1, 2026
Diagnostic accuracy of echocardiography in identifying heart failure related pleural effusionsAnuraag Sah, Matthew I Derakhshesh, Hannah D Bozell, et al.Nature Communications|April 7, 2022
STAG2 regulates interferon signaling in melanoma via enhancer loop reprogrammingZhaowei Chu, Lei Gu, Yeguang Hu, et al.JCO Precision Oncology|July 10, 2024
Phase II Trial of Afatinib in Patients With EGFR-Mutated Solid Tumors Excluding Lung Cancer: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol AScott N Gettinger, Zihe Song, Karen L Reckamp, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 10, 2021
Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus TrametinibJan C Brase, Robert F H Walter, Alexander Savchenko, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 12, 2020
Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131)Douglas B Johnson, Fengmin Zhao, Marcus Noel, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 27, 2011
Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging databaseJohn F Thompson, Seng-Jaw Soong, Charles M Balch, et al.Proceedings of the National Academy of Sciences of the United States of America|February 18, 2018
Molecular signatures of circulating melanoma cells for monitoring early response to immune checkpoint therapyXin Hong, Ryan J Sullivan, Mark Kalinich, et al.The New England Journal of Medicine|October 2, 2012
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutationsKeith T Flaherty, Jeffery R Infante, Adil Daud, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 22, 2024
Phase II Study of Palbociclib in Patients with Tumors with CDK4 or CDK6 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1CMark H O'Hara, Opeyemi Jegede, Mark A Dickson, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2007
Innovations and challenges in renal cell carcinoma: summary statement from the Second Cambridge ConferenceMichael B Atkins, Marc S Ernstoff, Robert A Figlin, et al.Pageof 40